AstraZeneca PLC
LSE:AZN
AstraZeneca PLC
Common Stock
AstraZeneca PLC
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
AstraZeneca PLC
LSE:AZN
|
Common Stock
$388m
|
CAGR 3-Years
0%
|
CAGR 5-Years
3%
|
CAGR 10-Years
2%
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Common Stock
£1.3B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Common Stock
$45m
|
CAGR 3-Years
12%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
|
Indivior PLC
LSE:INDV
|
Common Stock
$62m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-1%
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Common Stock
$40m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
|
A
|
Alliance Pharma PLC
LSE:APH
|
Common Stock
£5.4m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
8%
|
|
AstraZeneca PLC
Glance View
AstraZeneca PLC stands as a formidable entity in the global pharmaceutical landscape, adeptly navigating the intricate dance of innovation and commerce. Emerging from a merger between Sweden's Astra AB and the UK's Zeneca Group in 1999, the company has carved a niche through its relentless pursuit of cutting-edge medical solutions. Central to its operations is a sophisticated ecosystem of research and development, where thousands of scientists tirelessly explore the expansive frontier of biotechnology. The lifeblood of AstraZeneca's growth is its robust pipeline, where potential life-saving medicines traverse an arduous journey from laboratory benches to clinical trials, and eventually, regulatory approval. This rigorous process underscores its commitment to addressing complex diseases in areas such as oncology, cardiovascular, and respiratory health – domains marked by high unmet medical needs and significant market demand. The commercial prowess of AstraZeneca is equally vital to its success narrative. With a global reach spanning over 100 countries, the company leverages its advanced production facilities and strategic partnerships to deliver its pharmaceutical breakthroughs to those in need. Revenue generation is predominantly through the sale of prescription drugs, with blockbuster medications serving as pivotal financial pillars. These products, once approved, are strategically marketed to healthcare providers, ensuring they gain traction in various markets. AstraZeneca's approach is finely tuned to balance the scale of mass production with the nuance of catering to specific regional demands, maintaining a competitive edge in a crowded pharmaceutical landscape. Through these intricacies of innovation, production, and strategic market positioning, AstraZeneca not only generates substantial revenues but also reinforces its mission to improve patient health outcomes worldwide.
See Also
What is AstraZeneca PLC's Common Stock?
Common Stock
388m
USD
Based on the financial report for Dec 31, 2024, AstraZeneca PLC's Common Stock amounts to 388m USD.
What is AstraZeneca PLC's Common Stock growth rate?
Common Stock CAGR 10Y
2%
Over the last year, the Common Stock growth was 0%.
You don't have any saved screeners yet